Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 5/20 | 0.49 |
| ▸ | MMP13 | P45452 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14073146 | 0.94 | SMN1; SMN2 (0.61) | SMN1; SMN2TSHRPARP1KMT2AMAOA | |
| SCHEMBL14073142 | 0.88 | TSHR (0.57) | SMN1; SMN2TSHRPARP1KMT2AMAOA | |
| SCHEMBL8192214 | 0.84 | TSHR (0.53) | SMN1; SMN2TSHRPARP1KMT2AMAOA | |
| SCHEMBL14072944 | 0.84 | TSHR (0.53) | SMN1; SMN2TSHRPARP1KMT2AMAOA | |
| SCHEMBL14073181 | 0.84 | TSHR (0.53) | SMN1; SMN2TSHRPARP1KMT2AMAOA | |
| SCHEMBL14073367 | 0.83 | TSHR (0.53) | SMN1; SMN2TSHRPARP1KMT2AMAOA | |
| SCHEMBL14073514 | 0.81 | TRPV1 (0.59) | KMT2AALDH1A1MAPT | |
| SCHEMBL8198652 | 0.79 | PARP1 (0.57) | SMN1; SMN2TSHRPARP1KMT2AMAOA | |
| SCHEMBL14073116 | 0.78 | PARP1 (0.62) | TSHRPARP1KMT2AMAOAMMP8 | |
| SCHEMBL14072985 | 0.77 | TSHR (0.85) | TSHRPARP1MAOAMMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | SMN1; SMN2 3755/4885TSHR 4343/4885PARP1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.